- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/525 - Tumour necrosis factor [TNF]
Patent holdings for IPC class C07K 14/525
Total number of patents in this class: 713
10-year publication summary
|
56
|
56
|
69
|
51
|
58
|
46
|
45
|
56
|
38
|
24
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1285 |
23 |
| Apogenix AG | 72 |
22 |
| Universiteit Gent | 1341 |
17 |
| Vib VZW | 884 |
17 |
| Philogen S.p.A. | 126 |
15 |
| Shattuck Labs, Inc. | 123 |
15 |
| The General Hospital Corporation | 4759 |
13 |
| Universitat Stuttgart | 272 |
13 |
| Centre National de La Recherche Scientifique | 10498 |
11 |
| Centre hospitalier Regional universitaire de Montpellier | 30 |
11 |
| UCB Biopharma SRL | 580 |
11 |
| Cedars-Sinai Medical Center | 1163 |
10 |
| Sanofi Aatd Inc. | 17 |
10 |
| Immunicom, Inc. | 24 |
9 |
| Hoffmann-La Roche Inc. | 3456 |
8 |
| The Trustees of the University of Pennsylvania | 4335 |
8 |
| Apeptico Forschung und Entwicklung GmbH | 35 |
8 |
| Memed Diagnostics Ltd. | 75 |
8 |
| Thomas Jefferson University | 538 |
8 |
| Orionis Biosciences BV | 76 |
8 |
| Other owners | 468 |